POINT BIOPHARMA GLOBAL INC (PNT) Stock Overview
USA - NASDAQ:PNT - US7305411099 - Common Stock
PNT Key Statistics, Chart & Performance
The current stock price of PNT is 12.5 USD. In the past month the price decreased by -9.42%. In the past year, price increased by 71.47%.
PNT Latest News, Press Relases and Analysis
PNT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About PNT
Company Profile
POINT Biopharma Global, Inc. is a radiopharmaceutical company. The company is headquartered in Indianapolis, Indiana and currently employs 129 full-time employees. The company went IPO on 2020-07-10. The firm is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The firm is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.
Company Info
POINT BIOPHARMA GLOBAL INC
4850 West 78th Street
Indianapolis INDIANA US
CEO: Peter Kolchinsky
Employees: 129
Phone: 13175439957
POINT BIOPHARMA GLOBAL INC / PNT FAQ
What does POINT BIOPHARMA GLOBAL INC do?
POINT Biopharma Global, Inc. is a radiopharmaceutical company. The company is headquartered in Indianapolis, Indiana and currently employs 129 full-time employees. The company went IPO on 2020-07-10. The firm is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The firm is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.
What is the current price of PNT stock?
The current stock price of PNT is 12.5 USD. The price increased by 0.16% in the last trading session.
Does POINT BIOPHARMA GLOBAL INC pay dividends?
PNT does not pay a dividend.
What is the ChartMill technical and fundamental rating of PNT stock?
PNT has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about POINT BIOPHARMA GLOBAL INC (PNT) stock?
15 analysts have analysed PNT and the average price target is 15.05 USD. This implies a price increase of 20.36% is expected in the next year compared to the current price of 12.5.
What is the Price/Earnings (PE) ratio of POINT BIOPHARMA GLOBAL INC (PNT)?
The PE ratio for POINT BIOPHARMA GLOBAL INC (PNT) is 15.06. This is based on the reported non-GAAP earnings per share of 0.83 and the current share price of 12.5 USD.
Should I buy PNT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PNT.
PNT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PNT. When comparing the yearly performance of all stocks, PNT is one of the better performing stocks in the market, outperforming 97.1% of all stocks.
PNT Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PNT. PNT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
PNT Financial Highlights
Over the last trailing twelve months PNT reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 195.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 39.62% | ||
| ROA | 20.22% | ||
| ROE | 22.77% | ||
| Debt/Equity | 0.01 |
PNT Forecast & Estimates
15 analysts have analysed PNT and the average price target is 15.05 USD. This implies a price increase of 20.36% is expected in the next year compared to the current price of 12.5.
For the next year, analysts expect an EPS growth of 9.21% and a revenue growth -14.35% for PNT